Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07315113 | Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer | PHASE1 | RECRUITING | 18 | — | — | Dec 18, 2025 | Jun 1, 2027 | Jan 2, 2026 | 3 | United States |
Best response of complete response (CR) or partial response (PR) per RECIST 1.1
Confirmed CR or PR from the first documented response to the date of documented disease progression or death.
The proportion of patients with stable disease (SD), partial response (PR), or complete response (CR).
| Arm | Type | Description |
|---|---|---|
| Dose Exploration (Part 1) | EXPERIMENTAL | Escalating doses of NXP900 given with osimertinib |
| Name | Type | Description |
|---|---|---|
| NXP900 | DRUG | NXP900 is an orally administered inhibitor of SRC family kinases (SFK) |
| Osimertinib | DRUG | Osimertinib is an orally available, irreversible, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor |
Inclusion Criteria: 1. Provide written informed consent. 2. 18 years old or older. 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. 4. Unresectable, metastatic or locally advanced EGFR-mutated NSCLC. 5. Prior treatment with osimertinib as first or second line, as single agent...